Monte Rosa rises on J&J collaboration for cancer therapy trial (GLUE:NASDAQ)

Monte Rosa Therapeutics (GLUE) advanced in premarket trading on Monday as the company entered into a supply agreement with Johnson & Johnson (JNJ) to evaluate its MRT-2359 in combination with apalutamide for treating metastatic castration-resistant prostate cancer ...